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Looking Back, Moving Forward
Horizons studies 2002 to 2008
Access to AntiretrovirAl therApy for 
hiv infected Adults And children in 
developing countries
In 1997, the Population Council initiated the Horizons Program—a decade-long USAID-funded collabora-
tion with the International Center for Research on Women, the International HIV/AIDS Alliance, PATH, 
Tulane University, Family Health International, and Johns Hopkins University—designing, implementing, 
evaluating, and expanding innovative strategies for HIV prevention and care.
Horizons developed and tested ways to optimize HIV prevention, care, and treatment programs; worked to 
reduce stigma and improve gender-biased behaviors; and greatly expanded knowledge about the best ways to 
support, protect, and treat children affected by HIV and AIDS. In all its projects, Horizons strengthened the 
capacity of local institutions by providing support and training to colleagues.
This series of synthesis papers presents lessons learned and best practices on six key topics that Horizons 
investigated: HIV-related stigma, access to antiretroviral therapy, men who have sex with men, orphans and 
vulnerable children, HIV and gender, and prevention of mother-to-child transmission of HIV.
Credit: AVINA SARNA/POPULATION COUNCIL
Access to Antiretroviral Therapy 1
Introduction
In the late 1990s, increased accessibility of 
life-extending antiretroviral therapy (ART) 
changed the face of the AIDS epidemic around 
the world. Although Brazil, Thailand, Senegal, 
and Botswana were providing ART for adults 
through public sector health facilities as early 
as 2000, government treatment programs in 
other countries hard hit by HIV in the devel-
oping world were not established until 2002 
or later. ART services for children were started 
even later. Program managers in low resource 
settings rapidly raised questions regarding the 
best way to roll-out treatment programs: What 
were the key elements of health care readiness 
needed to offer ART services? What was the 
best way to train staff providing services? And 
what could be done to promote adherence to 
therapy? There was virtually no relevant evi-
dence to answer these questions. 
To respond to these questions, the Horizons 
Program convened a meeting of international 
experts in 2001 to explore the operational chal-
lenges related to the introduction of therapy in 
developing country settings and to prioritize 
research questions around access to ART [1]. 
Following this meeting Horizons embarked on 
a research program that eventually included 11 
projects (Appendix) across Asia and sub-Saha-
ran Africa examining service delivery, health 
Access to AntiretrovirAl therApy for 
hiv infected Adults And children in 
developing countries
The advent of life-saving antiretroviral therapy (ART) for people living with HIV 
in the late 1990s promised to avert millions of deaths to AIDS. However, in 
resource-constrained settings hard hit by the epidemic, providers and people living 
with HIV faced numerous challenges to the effective delivery and uptake of treat-
ment services. In 2001, Horizons began its investigation of the rollout and provi-
sion of ART in Asia and Africa in order to answer key questions surrounding service 
delivery, health seeking behaviors, adherence, cost, and barriers to treatment for 
HIV-infected adults and children. Horizons researchers found that provision of and 
adherence to ART regimens is hindered by a lack of knowledge among providers 
and affected communities, a lack of linkages between key services, and by stigma 
surrounding HIV. Our research has been used to break down these barriers and to 
guide global efforts toward ensuring full access and adherence to treatment across 
diverse settings.  
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seeking behaviors, adherence, cost and other 
factors affecting treatment for HIV-infected 
adults and children. The design and imple-
mentation of these studies raised additional 
questions regarding stigma, quality of life, and 
sexual risk behaviors among persons living with 
HIV on ART. This paper summarizes the key 
findings and lessons learned from these projects 
and provides recommendations for evidence-
based programming and future research around 
treatment for both children and adults. 
Lack of Provider Readiness, 
Community Awareness,  
Reduce Uptake and Adherence
Horizons initially undertook exploratory stud-
ies to document the experiences of programs 
that had already initiated ART services. These 
studies identified patient retention and ad-
herence to treatment as major challenges for 
scale-up. For example, a 2002 situation analy-
sis of the newly implemented Thai national 
ART program in 15 hospitals in five northern 
provinces documented a drop-out rate of 30 
percent in the first six months of the program, 
primarily because of side effects and lack of on-
going support. Types of non-adherence varied, 
including missed doses, not taking medica-
tions on time, and not following treatment 
instructions. 
A 2004 Horizons study of people living with 
HIV in India found adherence to be signifi-
cantly lower among patients with severe depres-
sion. Adherence was also lower among those 
receiving free ART compared to patients in the 
private sector who paid out-of-pocket for treat-
ment. The study highlighted the need for better 
patient education before initiating and during 
ART [2, 3].
Horizons’ research also revealed gaps in provid-
er training, confidence, and competency, which 
often prevented them from delivering ART ser-
vices. In Thailand, a majority of ART providers 
(i.e., doctors, nurses, and counselors) said they 
had trouble counseling patients on drug side ef-
fects (Table 1). Nearly half of doctors reported 
difficulties in diagnosing and managing side 
effects and drug interactions, despite receiving 
intensive training [4]. 
In a pediatric study in three Kenyan provinces 
selected because of high HIV prevalence and 
the availability of pediatric HIV care services, 
Table 1  Number and percentage of care providers who had difficulties in providing 
Access To Care Project services in northern Thailand (2002)
Item Doctors Nurses Pharmacists Counselors Total
n/N n/N n/N n/N n/N (%)
Diagnosis and management of 
side effects
3/7    4/11 3/8 10/26 (38)
Management of drug interaction 3/7  1/7 2/7  6/21 (28)
Counseling on drug side effects 5/6 14/18   6/10 3/4 28/38 (74)
Interpreting laboratory results 1/7   5/13 2/4  8/24 (33)
Management of opportunistic 
infections
2/8 1/6  3/14 (20)
Note:  N = number of care providers who responded to the question, n = number of those who had difficulties.
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health workers revealed 
knowledge gaps and low 
confidence regarding 





tion of mother-to-child 
transmission of HIV 
(PMTCT), and counsel-
ing [5]. A lack of stan-
dardized or coordinated 
training for health care 
workers on the manage-
ment of pediatric HIV 
was also identified in South Africa, where most 
doctors and nurses reported receiving no for-
mal training in ART, instead using self-study 
from books and online courses [6]. 
A study exploring practices in pediatric ART 
rollout at 16 sites in five South African prov-
inces found that nearly all of the children 
receiving ART were referred from community 
clinics or from inpatient wards. The vast major-
ity of children had been 
tested for HIV because 
they were chronically ill 
or hospitalized with a 
serious illness (Figure 1). 
Less than 2 percent of 
children receiving treat-
ment were referred from 
PMTCT programs [6]. 
The lack of follow-up 
care from PMTCT 
programs was particu-
larly notable. A study 
of HIV-positive preg-
nant and post-partum women in three high 
prevalence Indian states found that less than 
one-third had been informed about CD4 test-
ing, and only 18 percent were informed about 
the availability of ART during antenatal care. 
Of the women with living children, 44 percent 
reported that none of their children had been 
tested for HIV [7]. 
The Kenya pediatric study also included a 
community survey of primary caregivers of 
children [5]. The study found 
that while caregivers understood 
the basics of HIV in adults, 
knowledge about HIV infection 
and symptoms in children was 
low. Only half could name three 
symptoms indicative of pedi-
atric HIV infection. Although 
the majority were aware of treat-
ment options for HIV-infected 
children and believed that these 
children could live into adult-
hood, less than two-thirds knew 
where to access HIV testing and 
treatment services for children 
[5]. Health care costs (including 
those related to transport, con-
sultation fees, and medications) 
and HIV-related stigma also 
kept people from seeking care. 
“We are grossly under 
supplying antiretroviral drugs 
to children and our pre-
vention of mother-to-child 
transmission program is not 
working at this site. As a 
result children are dying in 
hoards.”
—Doctor (in a peri-urban setting) 
interviewed for a study of pediatric 
HIV treatment in South Africa 
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Frequent Clinic  
Visits, Enhanced  
Counseling, Support 
Adherence 
Directly observed therapy (DOT) 
is a treatment strategy originally 
developed for tuberculosis patients, 
who must take all their medications 
consistently and on time for up to 
nine months to rid themselves of 
the infection. In the standard DOT 
approach, health workers or com-
munity volunteers watch clients as 
they take their medication. One big 
difference between treatments for 
TB and HIV is that antiretroviral 
medications for HIV must be taken 
for life. A DOT strategy for AIDS 
treatment is called DAART, for 
“directly administered antiretroviral 
therapy.” A DAART program in-
cludes observation of patients tak-
ing their medications, but less often 
than for TB.
To develop a DAART program, Horizons re-
searchers explored the acceptability of home 
visits by health care workers versus clinic vis-
its among people with HIV, their preferred 
frequency of clinic visits per week, as well as 
the type of health worker they preferred for 
home visits. The majority of 
people interviewed preferred 
clinic-based DAART, citing 
confidentiality concerns and 
risk of stigma within the 
community associated with 
home health visits. Clients 
also believed that clinic visits 
afforded access to qualified 
health care workers and felt 
a sense of personal control 
by visiting the clinic instead 
of being visited at home [8]. 
Building on this research, 
acceptability of a clinic-based approach to 
DAART to promote adherence to ART was as-
sessed among HIV-infected persons accessing 
services in coastal Kenya [9]. Horizons con-
ducted one of the first randomized, controlled 
studies of a clinic-based, DAART intervention 
as a strategy to increase adherence to ART in a 
resource-constrained setting in Kenya. The in-
tervention consisted of twice 
weekly clinic visits for the 
first 24 weeks where patients 
met with DAART nurses 
who watched them taking 
their medicine, gave them 
more medications for the 
time between visits, counted 
pills, and counseled them 
on ways to continue taking 
their medication properly. 
Patients not getting DAART 
received standard monthly 
in-clinic follow up, includ-
ing counseling on taking 
medicine properly, and routine healthcare [10]. 
“It [DAART] reduced 
my anxiety about 
drugs. I got used to 
taking drugs. Also the 
drug dose timing; I was 
able to follow the time 
strictly.”
—33-year-old male patient 










Horizons researchers in Kenya found that DAART clients preferrred 
clinic-based visits with health workers over home-based visits due to 
confidentiality concerns and fear of stigma.
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cation at clinic and home visits; or (3) standard 
care consisting of routine counseling and clini-
cal follow up. The study found that enhanced 
counseling with and without peer involvement 
was effective in reducing drop-outs compared 
with standard care at 12 months, and that at 12 
months the peer intervention served to signifi-
cantly increase patients’ belief in their ability to 
take their ART properly [12].
Involving Community,  
Helping Individuals
While clinic-based interventions designed to 
increase an individual’s adherence to the ART 
regimen are important, effective community-
level interventions may also result in positive 
outcomes for people living with HIV. The 
AIDS Community and Education and Referral 
Strategy (ACER), in the Zambian cities of 
Lusaka and Ndola, represents one such effort. 
The intervention aimed to raise community 
awareness of HIV; strengthen community-
based support groups for peo-
ple living with HIV by incor-
porating traditional healers, 
church groups, and home-
based care services; establish 
referral mechanisms between 
health facilities and the com-
munity; and used volunteer 
peer treatment-support work-
ers at clinics [13]. A Horizons 
evaluation found few signifi-
cant differences in knowledge 
of HIV, disclosure of HIV 
status, and adherence to ART 
between communities that 
experienced the program and 
those that did not. It is likely 
that an unrelated clinic-based 
ART adherence program that 
was introduced in the com-
parison sites by another orga-
nization diluted the effects of 
the ACER intervention. 
The study found that DAART was feasible and 
effective in helping patients take their medi-
cine properly during the intervention period 
(Proportion with > 95% adherence: DAART: 
92 percent vs. non-DAART: 80 percent; p = 
0.012), but these effects were not sustained 
after the intervention [8, 11]. DAART was 
found to be particularly beneficial in patients 
with moderate or severe depression in the first 
24 weeks. The study findings raise further ques-
tions about the best way to optimize DAART 
and whether it is most effective amongst a 
sub-group of adults at risk for not taking their 
medicines properly [11]. 
In Thailand, Horizons researchers conducted a 
randomized controlled study to evaluate inter-
ventions to help people take their antiretroviral 
medications properly and reduce drop-outs 
at 45 hospitals across four northern provinces 
[12]. Hospitals were assigned to three groups: 
(1) enhanced adherence counseling, including 
patient education, side effect management, and 
integration of medication into daily life; (2) 





















Horizons researchers explored the impact of the AIDS Community 
and education and Referral Strategy (ACeR) in Zambia. Here, a 
treatment support worker talks to community members.
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Impact of ART on  
People Living with 
HIV
Stigma
Horizons researchers nested 
observational studies within 
intervention studies to examine 
change in HIV-related stigma 
among people with HIV who 
were receiving ART. These stud-
ies used an adapted HIV stigma 
scale covering four domains: 
personalized stigma, concerns 
about revealing their HIV sta-
tus, negative self-image, and 
concern with public attitudes 
[14]. Common themes from 
Horizons studies in Thailand 
[12], Zambia [13], and Kenya 
[15] showed that stigma decreased over time on 
ART. For example in Kenya the proportion of 
patients receiving ART reporting moderate to 
high stigma declined from 73 percent prior to 
initiating ART to 56 percent after 12 months 
of treatment (Figure 2). Internalized stigma 
appeared to be higher among female patients 
compared to male patients prior to initiating 
ART in Kenya [15] and Zambia [13]. 
Perceived quality of life
Perceived quality of life is a proxy for effective-
ness of medication regimens; if HIV is effec-
tively controlled, individuals have an increased 
sense of well-being and engagement in routine 
activities. Horizons’ researchers documented 
significant increases in quality of life measures 
over time among ART clients. 
In Thailand, significant improvements in men-
tal and physical health scores over 12 months 
following counseling for antiretroviral medica-
tion adherence and peer support were observed 
among patients in ART programs [12]. In 
Kenya, significant improvements occurred 
across general health perception; physical, so-
cial, and cognitive functioning; pain; mental 
health; and energy and fatigue. 
Gender
Horizons studies noted gender differentials in 
patient populations: more than 60 percent of 
Kenyan and Zambian patients and more than 
half of Thai patients were female [11–13]. Of 
note, no gender differentials in adherence to 
drug treatment were documented. 
Sexual risk behavior
Researchers have expressed concern that effec-
tive treatment and the increases in well-being 
and sexual activity that accompany it could 
lead to an increase in unprotected sex among 
people with HIV. Horizons research found 
no evidence of increased sexual risk behavior 
(i.e., multiple partners or unprotected sex) in 
Kenya [16–18], Thailand [19], Zambia [13], 
or India [3]. For example, in Kenya the pro-
portion of sexually active participants who 
reported unprotected sex with an unknown or 
HIV-negative partner declined from 50 percent 
at baseline to 28 percent after 12 months on 
Figure 2 Percent of participants with moderate to high stigma 
scores at baseline and follow up after 12 months of 
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treatment (Figure 3). However, unprotected 
sex is still prevalent, underscoring that the risk 
of HIV transmission remains, particularly with 
regular partners.
Testing and Validating  
Research Methods
Horizons used a diverse range of research meth-
odologies and study designs in its portfolio of 
research on access to treatment (Appendix). 
This includes measures and scales that were pre-
viously tested and validated, particularly those 
pertaining to adherence to antiretroviral drug 
regimens [20], depression [21], and quality of 
life [22, 23]. In some studies, scales were adapt-
ed by a team of expert psychologists and social 
scientists to more accurately reflect the local 
cultural context, and translations and back 
translations were pretested before application. 
In the absence of a gold standard, measuring 
adherence to antiretroviral drug regimens accu-
rately is a challenge especially in resource- 
limited settings. We recognize that patients 
often overstate their adherence to drug regi-
mens and under-report missed doses [24, 25]. 
Adherence studies often require that measures 
such as pill counts and self reports are under-
taken by clinic staff as a part of clinical man-
agement. Specialized training for interviewers 
to ensure consistent and accurate data collec-
tion with regard to these measuring techniques 
is essential. Newer methods such as computer-
ized pill counts and audio computer-assisted 
self-interviewing (ACASI) need to be explored 
further.
Moving Forward 
Horizons was among the first research pro-
grams to implement intervention studies on 
antiretroviral medication adherence in devel-
oping countries. The evidence base provided 
by Horizons’ early exploratory studies has 
contributed to the design, strengthening, and 
expansion of ART services. Horizons identified 
training gaps and a lack of provider confidence 
across several studies. Most treatment programs 
provide one-time, intensive provider training at 
their start. The importance of ongoing, need-
based, and interactive training for providers 
cannot be overemphasized. Training materials, 
such as the adherence counseling manual devel-
oped by Horizons and used in Kenya [8], are 
important in this endeavor, and have since been 



























Unprotected sex with 
HIV-negative or 
unknown status partners
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adapted by programs in Zambia, Tanzania, 
South Africa, and Russia. 
Human resource shortages in Africa are well 
documented [26], and some treatment pro-
grams are run by clinical officers and nurses 
instead of medical doctors. Expert consultation 
is needed as treatment regimens become more 
complicated. Future research will be needed 
to evaluate models of training programs with 
ongoing mentoring and access to specialist 
services. 
Horizons’ research has highlighted the lack of 
integration among services for HIV testing, 
TB testing, the prevention of mother-to-child 
transmission of HIV, maternal health, and 
ART. This information has been used by pro-
gram managers and departments of health, 
for example, in South African program plan-
ning efforts. In Kenya, the Kenya Network of 
Women with AIDS (KENWA) is developing 
interventions to increase community aware-
ness of pediatric HIV and treatment. Efforts to 
integrate HIV prevention care and treatment 
services into existing maternal and child health 
services require evaluation to identify best 
practices and successful models for scale-up. As 
programs race towards universal access to ART, 
it is imperative to explore new approaches to 
service delivery while simultaneously strength-
ening health systems and monitoring quality of 
services. 
DAART as a strategy to promote adherence has 
been evaluated largely among people who have 
HIV and are at risk of not taking their medica-
tions properly, such as injecting drug users [27–
29], patients in prison [30, 31] and to a limited 
extent among the general population [32, 33]. 
Horizons has added to the scientific evidence 
by rigorously evaluating clinic-based DAART 
in a resource-limited setting. Given that im-
provements in adherence were not sustained 
beyond the DAART intervention, further re-
search is needed to determine the optimum du-
ration of the intervention and ways to sustain 
its effects. This includes evaluating DAART 
among clients who have not taken their an-
tiretroviral medications properly over time, a 
population for whom this resource-intensive 
intervention might prove most beneficial. 
HIV programs have long used HIV-positive 
peers in developing countries as part of HIV-
prevention programs, for social support, and, 
to a limited extent, for treatment-related activi-
ties. However, before the mid-2000s there was 
no evaluation of a peer-based program designed 
to support people in taking their HIV drugs 
correctly. The Thailand Horizons study was one 
of the first to show that such interventions are 
more effective than standard care in increasing 
people’s belief in their ability to take their drugs 
correctly, lowering self-stigma, and improving 
quality of life. This intervention has been intro-
duced widely across the country with Global 
Fund assistance. Such interventions are costlier 
than traditional standard of care, and current 
scale-up of ART programs may exclude such 
ancillary services. Still, Horizons work in Kenya 
and Thailand showed the value of ancillary ser-
vices, including, DAART and peer education 
and support. 
Horizons studies were undertaken as ART 
programs first rolled out, and most patients 
presented with advanced HIV disease, a factor 
that undoubtedly stimulated adherence. As the 
epidemic matures, programs are increasingly 
managing patients on long-term treatment 
with emerging evidence of poor adherence to 
drug regimens [34]. Patients in resource-poor 
settings will experience side effects and other 
conditions associated with long-term ART, as 
has been documented in western countries [3, 
35–37]. These include diabetes and lipodystro-
phy, a redistribution of fat tissue on the body. 
It is not uncommon for people on long-term 
antiretroviral treatment, for example, to have 
gaunt faces and/or a “hump” on the back of 
their neck. Second-generation drug adherence 
studies in developing countries will need to 
examine these factors, as well as viral resistance, 
and their intersection with quality of life and 
stigma. For example, lipodystrophy might 
Access to Antiretroviral Therapy 9
serve as an identifier for HIV-positive individu-
als in the community, resulting in stigma and 
discrimination. 
Although Horizon’s studies provided no evi-
dence of an increase in sexual risk behavior 
among people with HIV who are on treatment, 
unprotected sex in regular partner relationships 
is prevalent, and the risk of HIV transmission 
is still a concern. Treatment programs need to 
emphasize risk reduction, condom use, and 
partner testing. Population Council researchers 
developed a “prevention with positives” inter-
vention to integrate prevention and treatment 
services in Kenya to address these issues.
Despite intense recent attention to pediatric 
treatment, access to treatment for HIV infected 
children has lagged behind that for adults [38, 
39]. Priority areas for research have included 
evaluation of interventions to increase diag-
nosis of HIV among children and to facilitate 
early treatment for HIV-infected children. The 
Population Council is supporting community 
interventions to increase the use of 
pediatric HIV testing and treatment 
services in Kenya, and has worked in 
South Africa on a family-centered ap-
proach to expand HIV testing of chil-
dren and the provision of pediatric 
care and treatment. Drug adherence 
programs for pediatric populations 
need to be developed and evaluated in 
Africa as more HIV-infected children 
receive treatment. Age is also an im-
portant consideration, as young chil-
dren, adolescents, and emancipated 
minors will have differing abilities to 
take their medications correctly.  
Horizons’ intervention studies also 
underscored the challenges of con-
ducting operations research in field 
settings. Of particular importance is 
the need for improved data collec-
tion methods and tools to accurately 
measure drug regimen adherence. 
Horizons’ partners at Chiang Mai University 
developed a computer-based program to in-
crease the accuracy of pill counts; such meth-
ods need to be evaluated. ACASI has been 
used in other Population Council studies ad-
dressing sensitive topics and could be applied 
to treatment research in order to improve the 
accuracy of self-reports of adherence. Selecting 
HIV-infected patients to participate in stud-
ies is challenging as people with HIV cannot 
be identified or reached in communities for 
reasons of confidentiality. Horizons’ researchers 
had to use convenience or quota sampling to 
overcome this problem [40]. Lastly, as in other 
sectors, sustaining interventions after initial 
funding ends is a challenge for both programs 
and researchers. For example, peer volunteers 
or community health workers play a key role 
in enhancing service delivery, but may require 
some form of compensation to continue deliv-
ering interventions.
Global efforts to expand access to HIV treat-




















A Horizons study in Chang Mai emphasized the need for improved data 
collection methods and tools to measure adherence to drug regimens.
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have resulted in significant progress. An esti-
mated 42 percent of the 9.5 million people in 
need of ART had access in 2008 [41]. While 
positive, this figure reflects the monumental 
task ahead to achieve universal access by 2015. 
Horizons’ research has made major contribu-
tions to the body of scientific evidence about 
ART provision and adherence, has answered 
key research questions, and has provided  
directions for next steps to reach universal 
access. 
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Sample characteristics and study design among Horizons studies, 2002–2008








A rapid situation analysis of 
the provision of highly active 
antiretroviral therapy to persons 
living with HIV/AIDS by the 
Ministry of Public Health’s Access 
to Care Project in Northern 
Thailand2
2002 HIV infected 
adults





Formative assessment of the 
acceptability of modified DOT 
strategy to promote adherence to 
ART among PLHA in Mombasa, 
Kenya9
2002 HIV infected 
adults  
38  PLHA Qualitative
Descriptive
Purposive sampling
Reproductive health services in 
KwaZulu Natal, South Africa: A 











Simple random sampling 
of health facilities
Convenience sampling of 
respondents
Operations research around the 
introduction of antiretrovirals in 
the management of HIV infected 










Quota sampling with 
randomized assignment
Assessment of adherence to 
treatment and sexual risk behaviour 
among HIV-positive patients 
receiving antiretroviral therapy—A 
diagnostic study in India3, 4
2004 HIV infected 
adults 
310 PLHA on 
treatment
Descriptive Quota sampling
Community education and 
referral: Supporting adherence 
to antiretroviral treatment and 














Cluster sampling of 
community members from 
households
Quota sampling of 
PLHA
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Reducing drop-outs and increasing 
adherence-rates among persons 
living with AIDS (PLA) on 












of facilities with random 
assignment to groups 
Quota sampling of 
PLHA
exploring current practices in 
pediatric ARV rollout and 
integration with early childhood 
programs in South Africa: A rapid 
situation analysis6








Diagnostic operations research to 
inform the national initiative on 
improving access to treatment, 
care and support for HIV-positive 








315 HIV infected 
females
Descriptive Convenience
exploring models of delivering ART 
and integration of ART with TB 
services in South Africa43








Healthy Start Pediatric HIV Study: 
A diagnostic study investigating 
barriers to HIV treatment and care 
among children in Kenya5
2007 HIV infected 
children
1,180 caregivers of 
children <15 yrs
103 health workers
Descriptive Cluster sampling of 
households
Convenience sampling of 
health workers
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